Sharapova slams ITF for lack of doping warning

Image
AFP London
Last Updated : Apr 14 2017 | 8:28 PM IST
Maria Sharapova hit out at tennis authorities today for failing to warn her that a drug she had been taken had become a banned substance.
Sharapova, a five-times Grand Slam champion, had an initial two-year suspension by the International Tennis Federation (ITF) reduced to 15 months after she tested positive at the 2016 Australian Open for meldonium.
This was a medication the Russian had been taking when it was within the rules but which was later reclassified as a prohibited drug.
"Why didn't someone come up to me and have a private conversation, just an official to an athlete, which would have taken care of the confidentiality problem they talked about later?" Sharapova told The Times.
However, she did accept she had become "complacent", saying she was responsible for failing the drug test.
"Ultimately the fault was mine," she added. "I had been getting clearance on everything I was taking for seven years and I became complacent."
Meldonium was added to the World Anti-Doping Agency list of banned substances at the start 2016 after increasing evidence that it enhanced performance.
Sharapova is set to make her return to competitive tennis at the WTA Stuttgart Grand Prix, which starts on April 24.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 14 2017 | 8:28 PM IST

Next Story